146 related articles for article (PubMed ID: 19909234)
1. Molecular targets in malignant pleural mesothelioma treatment.
Pasello G; Favaretto A
Curr Drug Targets; 2009 Dec; 10(12):1235-44. PubMed ID: 19909234
[TBL] [Abstract][Full Text] [Related]
2. Translational therapies for malignant pleural mesothelioma.
Belli C; Anand S; Tassi G; Fennell D; Mutti L
Expert Rev Respir Med; 2010 Apr; 4(2):249-60. PubMed ID: 20406091
[TBL] [Abstract][Full Text] [Related]
3. Targeted therapies in malignant pleural mesothelioma: a review of clinical studies.
Greillier L; Marco S; Barlesi F
Anticancer Drugs; 2011 Mar; 22(3):199-205. PubMed ID: 21263312
[TBL] [Abstract][Full Text] [Related]
4. Anti-angiogenic therapies for malignant pleural mesothelioma.
Ceresoli GL; Zucali PA
Expert Opin Investig Drugs; 2012 Jun; 21(6):833-44. PubMed ID: 22519641
[TBL] [Abstract][Full Text] [Related]
5. [Systemic Treatment of Malignant Pleural Mesothelioma].
Nakano T
Gan To Kagaku Ryoho; 2017 Dec; 44(13):2041-2047. PubMed ID: 29361614
[TBL] [Abstract][Full Text] [Related]
6. Antiangiogenic therapies for malignant pleural mesothelioma.
Yano S; Li Q; Wang W; Yamada T; Takeuchi S; Nakataki E; Ogino H; Goto H; Nishioka Y; Sone S
Front Biosci (Landmark Ed); 2011 Jan; 16(2):740-8. PubMed ID: 21196199
[TBL] [Abstract][Full Text] [Related]
7. Novel dual targeting strategy with vandetanib induces tumor cell apoptosis and inhibits angiogenesis in malignant pleural mesothelioma cells expressing RET oncogenic rearrangement.
Ogino H; Yano S; Kakiuchi S; Yamada T; Ikuta K; Nakataki E; Goto H; Hanibuchi M; Nishioka Y; Ryan A; Sone S
Cancer Lett; 2008 Jun; 265(1):55-66. PubMed ID: 18364248
[TBL] [Abstract][Full Text] [Related]
8. Receptor tyrosine kinase inhibitors and cytotoxic drugs affect pleural mesothelioma cell proliferation: insight into EGFR and ERK1/2 as antitumor targets.
Barbieri F; Würth R; Favoni RE; Pattarozzi A; Gatti M; Ratto A; Ferrari A; Bajetto A; Florio T
Biochem Pharmacol; 2011 Nov; 82(10):1467-77. PubMed ID: 21787763
[TBL] [Abstract][Full Text] [Related]
9. Molecular Pharmacology of Malignant Pleural Mesothelioma: Challenges and Perspectives From Preclinical and Clinical Studies.
Thellung S; Favoni RE; Würth R; Nizzari M; Pattarozzi A; Daga A; Florio T; Barbieri F
Curr Drug Targets; 2016; 17(7):824-49. PubMed ID: 26240051
[TBL] [Abstract][Full Text] [Related]
10. Antitumor effect and antiangiogenic potential of the mTOR inhibitor temsirolimus against malignant pleural mesothelioma.
Moriya M; Yamada T; Tamura M; Ishikawa D; Hoda MA; Matsumoto I; Klepetko W; Oda M; Yano S; Watanabe G
Oncol Rep; 2014 Mar; 31(3):1109-15. PubMed ID: 24378576
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase inhibitors in malignant pleural mesothelioma: preclinical rationale and clinical trials.
Paik PK; Krug LM
J Thorac Oncol; 2010 Feb; 5(2):275-9. PubMed ID: 20035240
[TBL] [Abstract][Full Text] [Related]
12. Moving beyond chemotherapy: novel cytostatic agents for malignant mesothelioma.
Kindler HL
Lung Cancer; 2004 Aug; 45 Suppl 1():S125-7. PubMed ID: 15261445
[TBL] [Abstract][Full Text] [Related]
13. All-trans-retinoic acid inhibits tumour growth of malignant pleural mesothelioma in mice.
Tabata C; Tabata R; Hirayama N; Yasumitsu A; Yamada S; Murakami A; Iida S; Tamura K; Terada T; Kuribayashi K; Fukuoka K; Nakano T
Eur Respir J; 2009 Nov; 34(5):1159-67. PubMed ID: 19443527
[TBL] [Abstract][Full Text] [Related]
14. SU6668, a multiple tyrosine kinase inhibitor, inhibits progression of human malignant pleural mesothelioma in an orthotopic model.
Van TT; Hanibuchi M; Goto H; Kuramoto T; Yukishige S; Kakiuchi S; Sato S; Sakaguchi S; Dat le T; Nishioka Y; Akiyama S; Sone S
Respirology; 2012 Aug; 17(6):984-90. PubMed ID: 22574723
[TBL] [Abstract][Full Text] [Related]
15. Systemic approach to malignant pleural mesothelioma: what news of chemotherapy, targeted agents and immunotherapy?
Signorelli D; Macerelli M; Proto C; Vitali M; Cona MS; Agustoni F; Zilembo N; Platania M; Trama A; Gallucci R; Ganzinelli M; Pelosi G; Pastorino U; de Braud F; Garassino MC; Lo Russo G
Tumori; 2016; 102(1):18-30. PubMed ID: 26481865
[TBL] [Abstract][Full Text] [Related]
16. E7080, a multi-tyrosine kinase inhibitor, suppresses the progression of malignant pleural mesothelioma with different proangiogenic cytokine production profiles.
Ikuta K; Yano S; Trung VT; Hanibuchi M; Goto H; Li Q; Wang W; Yamada T; Ogino H; Kakiuchi S; Uehara H; Sekido Y; Uenaka T; Nishioka Y; Sone S
Clin Cancer Res; 2009 Dec; 15(23):7229-37. PubMed ID: 19934291
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study.
Garland LL; Rankin C; Gandara DR; Rivkin SE; Scott KM; Nagle RB; Klein-Szanto AJ; Testa JR; Altomare DA; Borden EC
J Clin Oncol; 2007 Jun; 25(17):2406-13. PubMed ID: 17557954
[TBL] [Abstract][Full Text] [Related]
18. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.
Gordon GJ; Mani M; Maulik G; Mukhopadhyay L; Yeap BY; Kindler HL; Salgia R; Sugarbaker DJ; Bueno R
Cancer Chemother Pharmacol; 2008 Apr; 61(4):549-58. PubMed ID: 17522864
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma.
Jänne PA; Taffaro ML; Salgia R; Johnson BE
Cancer Res; 2002 Sep; 62(18):5242-7. PubMed ID: 12234991
[TBL] [Abstract][Full Text] [Related]
20. New agents in the management of advanced mesothelioma.
Vogelzang NJ; Porta C; Mutti L
Semin Oncol; 2005 Jun; 32(3):336-50. PubMed ID: 15988688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
